James Grua, MD
Endocrinology, Diabetes & Metabolism · West Valley City, UTNPI 1134159288
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Amryt Pharma Holdings Ltd at 48.0% of the total. Reporting peaked in 2022 at $8,300 and has fallen 94.6% since, to $447 in 2025.
Across 306 payments — averaging $50.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amryt Pharma Holdings Ltd$7K
- Recordati_rare_diseases_inc.$3K
- Amgen$2K
- Ascendis Pharma Endocrinology Inc$714
- Corcept Therapeutics$475
- Novo Nordisk$461
- plus $2K from 35 others
Across 10 payments — averaging $1747.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiasma, Inc.$7K
- Pfizer$6K
- Amryt Pharma Holdings Ltd$5K
What the payments were for
- Speaking & faculty fees$7,87551%
- Travel & lodging$1,65811%
- Food & beverage$5,76937%
- Education$1761%
- Entertainment$160%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amryt Pharma Holdings Ltd | 16 | $7,443 |
| Recordati_rare_diseases_inc. | 4 | $2,551 |
| Amgen | 57 | $1,516 |
| Ascendis Pharma Endocrinology Inc | 28 | $714 |
| Corcept Therapeutics | 20 | $475 |
| Novo Nordisk | 36 | $461 |
| AbbVie | 23 | $329 |
| Boehringer Ingelheim | 12 | $213 |
| Insulet Corporation | 11 | $181 |
| Pfizer | 13 | $174 |
| Ipsen Biopharmaceuticals, Inc | 8 | $160 |
| Merck | 9 | $133 |
| AstraZeneca | 9 | $127 |
| Xeris Pharmaceuticals, Inc. | 7 | $121 |
| Antares Pharma, Inc. | 8 | $114 |
| Lilly USA, LLC | 7 | $97 |
| Tandem Diabetes Care, Inc. | 5 | $82 |
| Strongbridge US Inc. | 2 | $66 |
| Medtronic(3 entities) | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| RGH Enterprises LLC | 1 | $38 |
| Rhythm Pharmaceuticals, Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $26 |
| Argenx US, Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $24 |
| BD | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Welch Allyn | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Vistapharm, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Optos, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Companion Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,513 in reported general payments places this provider in the 70th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 12 | $73,911 |
| Teriparatide | 12 | $25,780 |
| MounjaroTirzepatide | 11 | $12,901 |
| Levothyroxine Sodium | 515 | $5,812 |
| SynthroidLevothyroxine Sodium | 48 | $4,679 |
| Testosterone Cypionate | 62 | $4,053 |
| Hydrocortisone | 59 | $3,419 |
| Armour ThyroidThyroid,pork | 33 | $2,364 |
| Liothyronine Sodium | 46 | $2,225 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 12 | $1,937 |
| Raloxifene Hcl | 40 | $1,570 |
| Calcitriol | 34 | $1,404 |
| Desmopressin Acetate | 18 | $1,337 |
| Methimazole | 70 | $1,063 |
| Cabergoline | 22 | $890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerGenotropin | $174 | $73,91112 claims |
| Lilly USA, LLCMounjaro | $97 | $12,90111 claims |
| AbbVieSynthroid, Armour Thyroid | $329 | $7,04381 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $5,812515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in West Valley City
- Eliot BrintonSalt Lake City$733K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$241K
- Steven BrownLayton$105K
- Timothy GrahamSandy$90K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Priya KrishnamurthySt George$22K
- Vishnu SundareshSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.